Introduction
Vascular endothelial growth factor A (VEGF-A) has a crucial role in vascular development both in physiological and pathological processes. It is one of the key molecules shown to enhance angiogenesis and is thus considered as a potent therapeutic agent to stimulate blood vessel formation in myocardial and limb ischaemia. 1 However, since neovascularization is also associated with the growth and stability of atherosclerotic plaques, 2 the use of VEGF-A for therapeutic angiogenesis has been questioned. Although to date clinical trials involving hundreds of patients have not shown any indications of VEGF-A promoting or accelerating atherosclerosis and its clinical outcomes, 1 uncertainty concerning the role of VEGF-A in atherogenesis has remained due to inconsistent results from animal studies.
Regarding the role of angiogenesis in atherosclerosis, inhibition of intimal angiogenesis in apolipoprotein (apo) E knock-out (ApoE 2/2 ) mice 3 as well as vasa vasorum growth in LDLR 2/2 ApoB 100/100 mice 4 have been shown to reduce atherosclerosis, although in these studies the mechanisms were not specified to be directly VEGF-related. Also, DNA vaccination against VEGF receptor 2 has been shown to reduce atherosclerosis in LDLR 2/2 mice. 5 Based on these results, reducing angiogenesis in the vascular wall seems to slow down the growth of † S.E.H. and A.M.K contributed equally to this work. atherogenic plaques. However, when it comes to direct effects of VEGF overexpression, the results have been more variable. Pro-atherogenic effects were reported after single intraperitoneal or intramuscular injection of low-dose recombinant human (rh) VEGF-A in both ApoE 2/2 ApoB100 2/2 mice 6 and New Zealand white rabbits, 7 whereas systemic adenoviral gene transfers of human VEGF-A, -B, -C, or -D were not found to have any effects on either neovascularization or progression of lesions in LDLR 2/2 ApoB 100/100 mice. 8 The typical animal models used in atherosclerosis studies differ significantly from humans as well as from each other. Mice are naturally very resistant to atherosclerosis due to species-specific characteristics of lipoprotein metabolism. In humans, the most abundant apolipoprotein (apo) B subtype is apoB-100, which is produced only in the liver and is the major apolipoprotein component in Lp(a), VLDL, LDL, and intermediate density lipoprotein (IDL) particles. The minor subtype is apoB-48, which is synthesized in the intestine and functions in chylomicrons transporting ingested lipids into circulation for metabolic processing. However, some rodents, like rats and mice, are able to produce apoB-48 also in the liver. 9 Therefore, in mice, the majority ( 70%) of all VLDL produced in the liver carry apoB-48, in contrast to apoB-100 in humans. This leads to more rapid clearance of atherogenic apoBcontaining lipoproteins by the liver. Mice also lack CETP, which in humans transfers cholesterol esters from HDL to LDL and VLDL particles and triglycerides from VLDL to HDL. 10 Consequently, wild-type mice have a naturally low LDL and high HDL in which 90% of cholesterol is carried. Despite these differences, various hyperlipidaemic mouse models developed by genetic modification have offered unique tools for atherosclerosis studies. However, significant differences in lipoprotein metabolism exist between different mouse models and contradicting results concerning the role of VEGF-A in atherogenesis obtained from different mouse models could be due to some model-dependent factors. Therefore, the possibility that some effects of VEGF-A on atherosclerosis in mice would be mediated through lipid metabolism is intriguing. The present study aimed to find out potential factors explaining the contradictory findings obtained in different mouse models after VEGF-A administration, and to examine if the effect of VEGF-A is mouse model-dependent. Four common mouse models of atherosclerosis were used: LDLR 
Analyses of lipid metabolism
Triglycerides and total cholesterol were determined enzymatically using GPO-PAP kit (Ecolinew S+, Diasys, Diagnostic Systems Gmbh) and CHOD-PAP kit (Ecolinew 25, Merck KgaA), respectively. Blood samples for the analysis of lipoprotein fractions were withdrawn after an overnight fasting. Plasma (200 mL) from pools of 2-3 mice were fractionated by fast-performance liquid chromatography as described. 11 For the analysis of LPL activity, mice were fasted overnight, fed for 6 h and given an intravenous heparin bolus (100 U/kg, Heparin Leo). Blood samples were drawn 10 min after the heparin bolus and post-heparin plasma was isolated by centrifugation and frozen on dry ice. LPL activity was measured using a radiometric assay with a synthetic [
14 C]triolein substrate emulsified in the presence of 5% (w/v) gum arabic. 12 
Evaluation of atherosclerosis and lesion composition
Mice were sacrificed 1 month after gene transfer and thus a total western diet period of 2.5 months, and perfused with phosphate-buffered saline and 4% paraformaldehyde (PFA) (pH 7.4). Aortas were fixed in 4% PFA for 4 h and either embedded in paraffin and processed for lesion composition analysis or the adventitia was removed and the aortas were opened longitudinally and pinned out for en face evaluation. Lesion areas were quantified as described. 8 Analyses were performed in a blinded manner using AnalySIS software (Soft Imaging System GmbH).
To study lesion composition a modified Movat's pentachrome stain or immunostaining for macrophages (mMQ AIA31240, dilution 1:5000, Accurate Chemical & Scientific Corp) were used. 8 
Plasma and tissue levels of hVEGF-A and mVEGF-A
To evaluate endogenous mVEGF-A 164 expression levels in aortas, proteins from aortic tissue were extracted with T-PER tissue protein extraction reagent including Halt TM protease inhibitors (Pierce) and total protein contents were assayed with BCA TM protein assay kit (Pierce). Plasma levels of hVEGF-A 165 and tissue expression of endogenous mVEGF-A 164 were measured with enzyme-linked immunoassays (R&D).
RNA isolation and quantitative PCR
RNA was isolated with TRI-reagent (Sigma Aldrich). One microgram of total RNA was used for the cDNA synthesis using random hexamer primers (Promega) and RevertAid TM reverse transcriptase (Fermentas). The relative expression levels of mRNAs encoding LPL, hepatic lipase, Effects of VEGF-A on lipids and atherosclerosis hormone sensitive lipase, angiopoietin-like proteins (Angptl) 3 and 4, lipase maturation factor 1 (LMF1), glycosylphosphatidylinositolanchored high density lipoprotein-binding protein 1 (GPIHBP1), peptidylprolyl isomerase A (PPIA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in different tissue and cell samples were measured according to manufacturer's protocol with quantitative RT-PCR (StepOnePlus, Applied Biosystems) using specific Assays-on-Demand target mixes (Applied Biosystems). The expression levels were normalized to either PPIA or GAPDH.
Statistical analysis
Statistical analyses were performed using independent samples twotailed t-test (GraphPad Prism). The degree of association was measured by Pearson's correlation coefficient (r). Results are expressed as mean + SD and differences were considered statistically significant at *P , 0.05, **P , 0.01, ***P , 0.001.
Results

VEGF-A increased atherosclerotic lesion area in apoE-deficient models
To see if the contradicting results on the role of VEGF-A overexpression in atherogenesis were due to mouse model -specific factors, we first studied lesion areas and morphology in the four hyperlipidaemic strains. When the lesion area was examined en face in the whole aorta ( Figure 1A-F) , enhanced lesion development was observed in thoracic and abdominal aortas after AdVEGF-A gene transfer in apoE-deficient models: the effect of VEGF-A on lesion area was statistically significant only in ApoE 2/2 mice (P , 0.05) with a similar tendency in the LDLR 2/2 ApoE 2/2 group (P ¼ 0.058) ( Figure 1G ). However, no changes in lesion morphology after AdVEGF-A gene transfer were noticed in the different mouse models, and the majority of lesions represented macrophage-containing type II-III lesions ( Figure 1H -K).
VEGF-A induced alterations in lipid profiles and plasma lipid levels
In order to examine if the pro-atherogenic effects of VEGF-A observed in some mouse strains would be caused by changes in plasma lipids, lipoprotein profiles, and plasma levels of cholesterol and triglycerides were investigated. Four days after AdVEGF-A gene transfer, alterations in lipoprotein profiles compared with AdLacZ controls were seen in all four mouse models of hyperlipidaemia ( Figure 2) . In general, AdVEGF-A gene transfer increased the triglyceride proportion in large VLDL particles. In addition, when compared with the other models, the LDLR
2/2
ApoB 100/100 mice had decreased proportion of cholesterol in large VLDL particles ( Figure 2C ) and clearly increased proportion of phospholipids in HDL ( Figure 2M) . No major changes were seen in C57Bl6 mice after AdVEGF-A (Figure 2A, F, and K) . The effect of VEGF-A on total cholesterol and triglyceride levels was examined 4 and 14 days after gene transfer ( Figure 3 and see Supplementary material online, Table S1 ). On day 4, both AdLacZ and AdVEGF-A caused a general increase in plasma lipid levels, which most likely reflects the acute-phase inflammatory response to adenovirus. 13 No statistical differences in plasma lipids between AdLacZ and AdVEGF-A were seen in the atherosclerosis-prone models. On day 14, AdVEGF-A increased total cholesterol in LDLR 2/2 ApoB 100/100 and LDLR Table  S1 ). Also triglycerides tended to be elevated in LDLR 2/2 ApoB 100/100
and LDLR 2/2 mice, although the increases did not reach statistical significance. Plasma lipid levels of C57Bl6 mice were very low compared with other strains, as expected. However, changes similar to the LDLR-deficient models were seen in total cholesterol levels of C57Bl6 mice after AdVEGF-A ( Figure 3A and F and see Supplementary material online, Table S1 ). S.E. Heinonen et al.
VEGF-A reduced plasma LPL activity and tissue expression levels
To find an explanation for the changes seen in lipids, plasma LPL activity was measured (Figure 4) . No statistical differences were observed in LPL activity of AdLacZ-treated mice between different strains. However, compared with the AdLacZ controls, AdVEGF-A gene transfer reduced PHP-LPL activity by 40, 62, and 44% in ApoE 2/2 , LDLR 2/2 ApoE 2/2 , and LDLR 2/2 ApoB 100/100 mice, respectively ( Figure 4E ). In LDLR-deficient models plasma hVEGF-A levels were significantly lower compared with apoE-deficient models ( Figure 4F ), however, it was noted that the PHP-LPL activity correlated negatively with plasma hVEGF-A levels in all studied mouse models ( Figure 4A-D) . No differences in the amount of endogenous mVEGF-A 164 in aortas or plasmas were seen between the four models (data not shown) and therefore its contribution to the observed effects is unlikely. To clarify the mechanism underlying the effect of VEGF-A on LPL, we first examined LPL mRNA expression in the heart, liver, muscle (m. rectus), and white adipose tissue (WAT) after gene transfers. VEGF-A was shown to reduce LPL activity in all models, and therefore the following mechanistic studies were carried out in one strain, the LDLR
2/2
ApoB 100/100 mice. Interestingly, 4 days after gene transfer, VEGF-A caused a significant 25% reduction (P ¼ 0.015) in LPL mRNA expression in the heart ( Figure 5A ) and a 22% reduction (P ¼ 0.020) in the WAT ( Figure 5B ) compared with control virus. No change in LPL mRNA level was seen in the liver or muscle (data not shown). Since a reduction in LPL mRNA or protein levels does not necessarily explain or even correlate with the enzyme activity, we next looked into other possible mechanisms of interaction by measuring the expression of Angptl3 and 4, LMF1, and GPIHBP1, genes that are known to regulate LPL activity in a post-translational manner.
14 Surprisingly, VEGF-A significantly increased the Angptl4 mRNA level in the heart and WAT compared with control ( Figure 5C and D), whereas expression of other genes remained unchanged (data not shown). These findings were also confirmed in vitro using 3T3-L1 pre-adipocytes, where rhVEGF-A caused a significant 26 + 6% reduction in LPL mRNA level compared with a nontreated control ( Figure 6A ). In addition, Angptl4 mRNA level was increased by rhVEGF-A ( Figure 6B) . Furthermore, the possible effect of VEGF-A on the other members of the triacylglycerol lipase family, hepatic lipase and hormone sensitive lipase, was studied. Hormone sensitive lipase in the WAT and hepatic lipase in the liver remained unchanged after AdVEGF-A gene transfer (data not shown). However, we recently showed that VEGF-A is also able to decrease endothelial lipase expression both in vitro and in vivo, 15 which could explain the increased proportions of phospholipids in HDL seen in lipoprotein profiles in the present study (Figure 2 ).
Discussion
In the present study, we examined the short-term effects of AdVEGF-A gene transfer on atherosclerosis in four different mouse models of hyperlipidaemia. The results demonstrate that overexpression of VEGF-A is more atherogenic in mouse models with apoE deficiency. More importantly in metabolic terms, VEGF-A induced changes in lipoprotein profiles and increased the triglyceride proportion of large VLDL Effects of VEGF-A on lipids and atherosclerosis particles. Furthermore, the role of LPL was investigated and a negative correlation between plasma VEGF-A levels and PHP-LPL activity was found in all models. The negative correlation between plasma LPL activity and VEGF-A levels was an unexpected finding. LPL hydrolyses core triglycerides in chylomicrons and VLDLs, producing chylomicron remnants and IDLs that are normally rapidly cleared from plasma via apoE-mediated hepatic uptake. 16 Therefore, it could be hypothesized that consequences of reduced LPL activity are further accentuated in apoEdeficient models and they are more strongly affected than LDLR-deficient models. However, if looking into the lipid profiles and plasma lipid levels, this was not the case. Even if VEGF-A decreased LPL activity in all models, a subsequent increase in triglyceride proportions in VLDL particles was largest in LDLR 2/2 ApoB 100/100 mice.
These mice also had a decreased proportion of cholesterol in VLDL, most probably due to a shift towards more triglyceride-rich particles. The major difference between LDLR 2/2 ApoB 100/100 mice and the other models is that the LDLR 2/2 ApoB 100/100 mice lack apoB-48 which is the major apoB subtype in all the other models. Hepatic lipase is also able to hydrolyse triglycerides in large lipoprotein particles but seems to prefer apoB-48-containing particles over those with apoB-100. 17, 18 This could partly explain why triglyceride accumulation in VLDL particles was most severe in LDLR 2/2 ApoB 100/100 mice. Furthermore, unlike the apoE-deficient mice, both LDLR 2/2 and LDLR
2/2
ApoB 100/100 mice showed significantly increased total cholesterol levels 14 days after AdVEGF-A gene transfer compared with control. This suggests that in the case of normal LPL activity, intact apoE present in LDLR 2/2 and LDLR 2/2 ApoB 100/100 models is able to facilitate cholesterol clearance by a mechanism independent of the LDLR as well as of the LDLR-related protein, which plays part only in the uptake of apoB-48-containing lipoproteins. 19 But when LPL activity is reduced after AdVEGF-A gene transfer, this clearance mechanism seems to be deficient as the total cholesterol levels in LDLR 2/2 and LDLR
ApoB 100/100 models increase. In fact, it has been shown that apoEmediated uptake of lipoproteins by VLDLR, scavenger receptor class B type I (SR-BI) and proteoglygans is at least partly dependent on LPL activity.
20,21
The effect of VEGF-A on LPL activity as a novel finding also raised a question about the possible mechanism. LPL is regulated at transcriptional, post-transcriptional, translational, and post-translational levels in a tissue-specific manner.
14 Despite the extensive research on tissuespecific regulation of LPL, the complex mechanisms have remained mostly unknown. 14 To elucidate the mechanism of action of VEGF-A on LPL, we first examined the expression of LPL in different tissues at mRNA level. Interestingly, VEGF-A reduced significantly LPL mRNA in the heart and WAT. Since the actual activity of LPL does not necessarily correlate with its mRNA or protein levels, 22 it is possible that also other VEGF-A-mediated effects contributed specifically to the reduced activity. Therefore, we examined the tissue expression of interactive proteins that are shown to participate in LPL regulation: Angptl3 and 4, LMF1, and GPIHBP1.
14 Surprisingly, VEGF-A significantly increased the mRNA level of Angptl4 in the heart and WAT. It has been shown that Angptl4 deficiency in mice leads to increased levels of heparin-releasable LPL activity and decreased plasma triglyceride levels, whereas overexpression of Angptl4 decreases LPL activity and increases plasma triglycerides. 23 Thus, increased Angptl4 expression could contribute to the decreased LPL activity after AdVEGF-A gene transfer in the present study. This was supported also by in vitro studies, where VEGF-A increased Angptl4 mRNA and decreased LPL mRNA in 3T3-L1 pre-adipocytes. Altogether, VEGF-A seems to regulate LPL at least in two ways: transcriptionally by reducing LPL mRNA itself, and post-translationally by decreasing its activity via increasing Angptl4 expression.
Although the same amount of virus was used in all models, the plasma levels of hVEGF-A were significantly lower in LDLR 2/2 and LDLR
2/2
ApoB 100/100 mice compared with the apoE-deficient models. The reason for this is unknown, but could relate to some lipid-virus interactions: it has been reported that lipoproteins are able to neutralize a wide variety of viruses. 13 In addition, some viruses are able to use members of the LDL receptor family for entry into cells, an uptake mechanism competed by increased plasma lipid levels. S.E. Heinonen et al.
Nevertheless, the amount of hVEGF-A was sufficient to decrease LPL activity in all models and LDLR 2/2 and LDLR 2/2 ApoB 100/100 mice appeared to be even more sensitive to the decreased LPL activity than apoE-deficient models. However, increased atherosclerotic lesion area after AdVEGF-A was only seen in the models lacking apoE. This discrepancy implies firstly that the lipid changes following a 40 -60% decrease in LPL activity were not enough to affect atherogenesis in the LDLR 2/2 models. This is not unexpected, since in human subjects heterozygous for the LPL gene, 30 -50% decrease in LPL activity causes only modestly elevated concentrations of plasma triglycerides and even no changes in total cholesterol. 24, 25 On the other hand, it also suggests that the reduction in LPL activity was unlikely to play a significant role in the increased atherosclerosis of the apoE-deficient models, leaving it open if some other VEGF-mediated effects influenced the atherogenesis in these strains. In ApoE 2/2 mice, VEGF-A has reported to be pro-atherogenic via increased plaque angiogenesis. 6 However, this was not seen in our previous study with LDLR 2/2 ApoB 100/100 mice and systemic AdVEGF-A administration. 8 The differences in lipoprotein profiles between these mouse strains could contribute to this inconsistency, since it has been shown that apoB-100-containing lipoproteins are able to inhibit angiogenesis via up-regulation of VEGF receptor 1, a decoy receptor for VEGF-A. 26 As the LDLR 2/2 and LDLR
ApoB 100/100 mice have six-and nine-fold higher plasma levels of apoB-100 particles compared with ApoE 2/2 mice, 19 it could protect these models from VEGF-A induced angiogenesis and subsequent progression of atherosclerotic lesions. Moreover, adding to the complexity of the interaction between VEGF-A and lipid metabolism, a common genetic regulation between VEGF-A and cholesterol homeostasis molecules was recently reported. 27 Therefore, considering the increasing evidence and the effects seen in the present as well as in our previous study, 15 it seems that VEGF-A clearly plays a role in the regulation of lipid metabolism and that also some other, still unknown, mechanisms may be involved.
In conclusion, we have studied the short-term effects of AdVEGF-A gene transfer on atherogenesis, lipoproteins, and LPL in four different atherosclerosis-prone mouse models. Since VEGF-A only increased atherosclerotic lesion formation in apoE-deficient mice, the use of different mouse models for studying the role of VEGF-A in atherogenesis is likely one major factor explaining the contradictory results seen in the literature. As a novel finding, we report a negative correlation between plasma VEGF-A and PHP-LPL. The effects of VEGF-A on LPL activity 4 days after control LacZ and VEGF-A gene transfers (E). The plasma levels of hVEGF-A 4 days after VEGF-A gene transfer (F ). Each bar represents mean + SD, n ¼ 4 -8 per group. *P , 0.05 and **P , 0.01 when compared with the respective control group.
Effects of VEGF-A on lipids and atherosclerosis LPL seemed to be mediated through both direct transcriptional regulation, and post-translationally by increasing Angptl4. To the best of our knowledge, this connection between VEGF-A and LPL has not been reported before. Since increasing amount of data is suggesting that VEGF-A is involved in the regulation of lipid metabolism, further investigations are needed to elucidate the specific mechanisms and to provide information highly important for the therapeutic use of VEGF-A.
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